OakChart

Immix Biopharma Inc

IMMXHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 3:59 PM ET

8.07-0.59 (-6.81%)
2026-11-13 06:43 CET
Market cap
$669.03M
Revenue, TTM
0.00 USD m
Net income, TTM
-39.92 USD m
Free cash flow, TTM
-39.09 USD m
EPS diluted, TTM
-0.88
Price / earnings
-
Compare

Price

IMMX against its 20, 50 and 200-day averages
Terms2050200BeatEarnings
Patternshover a marker to name it
RS 54R -0.21Price-0.21-0.195.007.5010.0012.5015.003.7M7.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMMXclose 8.0720-day 8.0950-day 9.94200-day 9.618.0752w high 15.1052-week range, not 6 months

46.6% under the 52-week high of 15.10 on 25 Aug 2026. 52-week low 3.26 on 12 Nov 2025. Last 15 sessions, 24.9% high to low

Volume 0.64× normal · the line is the 50-bar volume average

Setup. RS line 54
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 4 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 2 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Accumulation 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Relative Strength 2 of 3 — fails: 200-Day Simple Moving Average: Price above SMA200

Profile

IMMX
52-week range, 41% of the way up
3.2615.10

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

IndexRUT
Employees21
IPODec 16, 2021
Beta0.29
ATR, 14d0.66
Rel volume0.64
Short float16.50%
Insider own17.71%
Inst own69.97%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$669.03M
Enterprise Value437.92M
Income-39.92M
Sales0.00M
Book / share3.20
Cash / share2.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees21
IPODec 16, 2021

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book2.52
Price / cash2.88
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio25.13
Current Ratio25.13
Debt / equity0.00
Long-term debt / equity0.00
Options and shortYes / Yes

Earnings

Earnings / share-0.88
Earnings next year-0.95
Earnings next quarter-0.19
Earnings this year18.98%
Earnings next year-31.39%
Earnings growth, 5 years9.33%
Past earnings growth-12.81% -43.32%
Past sales growth- -
Earnings vs last year-11.21%
Sales vs last year-
Earnings vs last quarter17.97%
Sales vs last quarter-
EarningsSep 02
Surprise-2.51% -

Ownership

Insiders own17.71%
Insider trades0.00%
Institutions own69.97%
Institution trades56.49%
Return on assets-31.34%
Return on equity-34.18%
Return on capital-17.37%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-0.29%
50-day average-18.79%
200-day average-15.99%

Technical

Shares out71.54M
Shares floating68.22M
Short / float16.50%
Short ratio7.56
Short interest11.25M
52-week high15.10 -46.6%
52-week low3.26 +147.5%
Volatility9.00% 7.83%
Average range0.66
Strength index44.49
Market sensitivity0.29
Relative volume0.64
Avg Volume1.49M
Volume960,314

Performance

Perf Week12.08%
Perf Month-5.17%
Perf Quarter-26.44%
Perf Half Y-20.10%
Perf YTD54.30%
Perf Year116.94%
Perf 3Y92.60%
Perf 5Y-
Perf 10Y-
Recommendation1.00
Target Price24.05
Prev Close8.66
Price8.07
Change %-6.81%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jul 22, 2026InitiatedNeedhamBuy$21+160.2%
Jun 18, 2026InitiatedBofA SecuritiesBuy$27+234.6%
Mar 25, 2026InitiatedMorgan StanleyOverweight$20+147.8%
Mar 09, 2026InitiatedCitizensMkt Outperform$23+185.0%
Feb 09, 2026InitiatedMizuhoOutperform$14+73.5%

Peers

Mkt cap
TickerCompanyMkt cap
LEGNLegend Biotech Corp ADR3.60B
PRTAProthena Corp Plc422.61M
AUTLAutolus Therapeutics plc ADR316.94M
ALLOAllogene Therapeutics Inc286.53M
KYTXKyverna Therapeutics Inc311.07M
CABACabaletta Bio Inc286.90M
FATEFate Therapeutics Inc162.90M
CRBUCaribou Biosciences Inc41.08M
ALNYAlnylam Pharmaceuticals Inc20.98B
NKTXNkarta Inc90.70M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Rachman Ilya MCEO and ChairmanDec 10 '25Buy6.677464,9761,141,683Dec 10 06:49 PM
Morris Gabriel SCFODec 10 '25Buy6.587705,067291,429Dec 10 06:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
XBIState Street SPDR S&P Biotech ETFAUM: 10.59B
IWMiShares Russell 2000 Index FundAUM: 77.86B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 396.75M
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.88B
IWCiShares Micro-Cap ETFAUM: 1.23B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 96.50B

News

latest 14 of 200
  • Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress (GlobeNewswire) -6.81%
  • Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 (GlobeNewswire)
  • Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
  • Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock (GlobeNewswire)
  • BofA Raises Odds Of Success For Immix Biopharmas NXC-201 Therapy Sees Over 190% Upside In IMMX Stock (Stocktwits) -8.11%
  • Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial (InvestorsHub)
  • Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock (GlobeNewswire)
  • Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
  • Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire) +10.81%
  • Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? (Quartz)
  • Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire)
  • Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock (GlobeNewswire)
  • Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 (GlobeNewswire)
  • Immix Biopharma to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +11.43%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.176-0.171-0.1700.000.007
2026Q12026-06-03-0.180-0.181-0.1820.000.004
2025Q42026-02-25-0.265-0.145-0.2790.000.002
2025Q32025-12-03-0.240-0.240-0.2380.00-1
2025Q22025-09-03-0.220-0.160-0.2210.00-1
2025Q12025-05-28-0.150-0.230-0.1530.00-1
2024Q42025-02-26-0.250-0.250-0.1750.00-1
2024Q32024-11-27-0.240-0.160-0.2430.00-1
2024Q22024-08-28-0.150-0.150-0.1530.00-1
2024Q12024-05-29-0.230--0.2240.00--
2023Q32023-11-29-0.230-0.230-0.2300.000.001
2023Q22023-08-30-0.240-0.240-0.2380.000.001
2023Q12023-08-02-0.180--0.1780.00-1
2022Q42023-03-31-0.270-0.220-0.2870.000.001
2022Q32023-02-21-0.110--0.1100.00--
2026Q3---0.185--0.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-0.575-0.520-0.6220.000.00
2023FY-0.750-0.795-0.8900.000.00
2024FY-0.715-0.795-0.7640.001.00
2025FY-0.877-0.663-0.8900.000.00
2026FY--0.721--0.00
2027FY--0.948--26.40
2028FY--0.663--153.91
2029FY--0.625--246.99
2030FY-1.280--486.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-024000.000.000.00
2026Q3S2026-08-074000.000.000.00
2026Q3S2026-06-183000.000.000.00
2026Q3S2026-06-032000.000.000.00
2026Q3S2026-03-262000.000.000.00
2026Q3S2026-03-061000.000.000.00
2026Q3R2026-10-28201-0.21-0.21-0.20
2026Q3R2026-10-27202-0.21-0.21-0.20
2026Q3R2026-09-02101-0.20-0.20-0.20
2026Q3R2026-08-14101-0.20-0.20-0.20
2026Q3R2026-08-06100-0.17-0.17-0.17
2026Q3R2026-06-18200-0.18-0.19-0.17
2026Q3R2026-06-03100-0.19-0.19-0.19
2026Q3R2026-04-28100-0.19-0.19-0.19

Estimate history

EPS, annual-0.125-0.148-1.843-0.622-0.89-0.764-0.893-0.8802
Period2019202020212022202320242025TTM
EPS, quarterly-0.153-0.243-0.175-0.153-0.221-0.238-0.279-0.182-0.181
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual7.7747.77413.22913.22919.92227.5452.95171.536
Period2019202020212022202320242025MRQ
Shares, quarterly27.42927.48127.5427.85228.40633.03652.95153.01271.536
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.490.360.120.010.000.000.000.00
Gross Profit-0.49-0.36-0.12-0.01-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other41.2426.8522.5216.138.221.350.450.84
Research and Development21.5213.5311.298.744.200.130.250.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-41.73-27.21-22.64-16.14-8.22-1.35-0.45-0.84
Interest Expense0.000.000.000.000.000.180.100.11
Unusual Expense0.000.000.000.000.0022.850.570.00
Net Income Before Taxes-39.88-29.40-21.66-15.57-8.22-24.38-1.13-0.95
Income Taxes0.030.040.040.030.010.010.020.02
Consolidated Net Income-39.92-29.44-21.70-15.60-8.23-24.38-1.15-0.97
Net Income From Continuing Operations-39.92-29.44-21.61-15.43-8.23-24.38-1.15-0.97
Net Income-39.92-29.44-21.61-15.43-8.23-24.38-1.15-0.97
EPS (Recurring)-0.63-0.89-0.76-0.89-0.62-0.63-0.10-0.13
EPS (Basic, Before Extraordinaries)-0.88-0.89-0.76-0.89-0.62-1.84-0.15-0.13
EPS (Diluted)-0.88-0.89-0.76-0.89-0.62-1.84-0.15-0.13
EBITDA-41.24-26.85-22.52-16.13-8.22-1.35-0.45-0.84
Non-Operating Income (Expense)1.84-2.190.980.570.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.911.531.891.540.410.12--
Shares Outstanding71.5452.9527.5419.9213.2313.237.777.77
Market Capitalization669.03669.0360.52135.6931.8925.6323.47-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.130.090.130.080.060.040.03
Gross Profit-0.13-0.13-0.09-0.13-0.08-0.06-0.04-0.03
Selling, General and Administrative Excl. Other12.3310.6810.707.536.634.614.937.37
Research and Development5.335.985.634.583.971.981.374.45
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.47-10.81-10.79-7.66-6.71-4.67-4.97-7.39
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-11.54-10.09-10.68-7.58-6.61-4.53-4.80-7.14
Income Taxes0.010.000.010.010.010.010.010.01
Consolidated Net Income-11.56-10.09-10.69-7.59-6.62-4.54-4.81-7.15
Net Income From Continuing Operations-11.56-10.09-10.69-7.59-6.62-4.54-4.81-7.15
Net Income-11.56-10.09-10.69-7.59-6.62-4.54-4.81-7.15
EPS (Recurring)-0.18-0.18-0.28-0.24-0.22-0.15-0.17-0.24
EPS (Basic, Before Extraordinaries)-0.18-0.18-0.28-0.24-0.22-0.15-0.17-0.24
EPS (Diluted)-0.18-0.18-0.28-0.24-0.22-0.15-0.17-0.24
EBITDA-12.33-10.68-10.70-7.53-6.63-4.61-4.93-7.37
Non-Operating Income (Expense)0.920.720.110.090.100.140.170.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.720.510.370.320.370.480.480.58
Shares Outstanding71.5453.0152.9533.0428.4127.8527.5427.48
Market Capitalization669.03482.51275.6060.2657.7146.5760.5240.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments100.4117.6817.5113.4417.640.390.73
Short Term Receivables0.001.971.170.260.030.130.18
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.830.541.111.210.520.010.02
Total Current Assets101.2420.2019.7914.9018.190.530.93
Net Property, Plant & Equipment3.492.730.050.000.010.010.01
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets--0.00-0.000.000.00
Other Assets0.110.020.090.010.000.000.00
Total Assets104.8422.9519.9314.9118.190.540.94
Short Term Debt Incl. Current Port. of LT Debt0.140.070.000.000.054.104.10
Accounts Payable5.445.391.431.270.140.250.25
Other Current Liabilities4.533.232.290.000.010.920.24
Total Current Liabilities10.118.693.721.270.205.274.59
Long Term Debt0.931.010.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.470.000.000.00
Total Liabilities11.049.703.721.750.205.274.59
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity93.8013.2516.4113.1617.99-4.73-3.65
Total Shareholders Equity93.8013.2516.4113.1617.99-4.73-3.65
Accumulated Minority Interest0.000.00-0.200.000.000.000.00
Total Equity93.8013.2516.2013.1617.99-4.73-3.65
Total Liabilities & Stockholders Equity104.8422.9519.9314.9118.190.540.94
Book Value Per Share1.770.480.820.991.36-0.61-0.47
Tangible Book Value Per Share1.770.480.820.991.36-0.61-0.47
Full-Time Employees212117119--
Price to Book Ratio2.523.446.861.902.62-4.09-
Return on Assets-46.07-100.83-88.57-49.73-260.35-154.85-
Return on Equity-55.00-145.76-104.35-52.84-367.80--
Return on Invested Capital-31.08-151.56-94.03-62.54-135.54--
Quick Ratio10.012.335.3211.7090.010.100.20
Current Ratio10.012.335.3211.7090.010.100.20

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-39.92-29.44-21.70-15.60-8.23-24.38-1.15-0.97
Depreciation0.490.360.120.010.000.000.000.00
Other Funds (Non Cash)2.582.443.022.570.6223.180.570.00
Funds from Operations-36.85-26.63-18.56-13.02-7.60-1.20-0.57-0.97
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-1.652.703.971.650.20-0.390.170.18
Cash from Operating Activities-38.50-23.93-14.60-11.37-7.41-1.59-0.40-0.79
Capital Expenditures-0.59-0.73-1.18-0.050.00-0.000.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-8.56-6.480.000.000.000.000.000.00
Purchase of Investments-18.80-6.480.000.000.000.000.000.00
Sale Or Maturity of Investments10.240.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-9.15-7.21-1.18-0.050.00-0.000.00-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock261.52107.3915.9515.702.8118.650.000.00
Repurchase of Common Pref Stock0.000.000.000.00-0.100.000.000.00
Sale of Common Pref Stock261.52107.3915.9515.702.9118.650.000.00
Proceedsfrom Stock Options261.35107.2615.9515.702.9118.650.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-0.050.200.001.05
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.230.470.000.000.00
Other Financing Activities Uses0.000.000.00-0.23-0.010.000.000.00
Cash from Financing Activities261.52107.3915.9515.463.2318.850.001.05
Exchange Rate Effect-0.020.00-0.000.03-0.03-0.010.060.02
Net Change in Cash213.8576.250.174.07-4.2117.25-0.340.27
Free Cash Flow-39.09-24.66-15.77-11.42-7.41-1.59-0.40-0.80
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments232.1190.58100.4115.9511.6415.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.681.700.830.640.690.86
Total Current Assets233.7992.27101.2416.5812.3316.78
Net Property, Plant & Equipment3.253.363.493.363.183.09
Total Investments and Advances2.050.000.000.000.000.00
Other Assets0.020.190.110.130.130.02
Total Assets239.1195.82104.8420.0815.6419.89
Short Term Debt Incl. Current Port. of LT Debt0.110.130.140.140.070.07
Accounts Payable5.284.735.447.056.615.74
Other Current Liabilities3.915.684.533.663.323.50
Total Current Liabilities9.3010.5410.1110.8510.019.31
Long Term Debt0.890.910.930.970.970.99
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.1911.4511.0411.8210.9810.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity228.9284.3693.808.264.659.59
Total Shareholders Equity228.9284.3693.808.264.659.59
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity228.9284.3693.808.264.659.59
Total Liabilities & Stockholders Equity239.1195.82104.8420.0815.6419.89
Book Value Per Share3.201.591.770.250.160.34
Tangible Book Value Per Share3.201.591.770.250.160.34
Full-Time Employees--21---
Price to Book Ratio2.525.1420.9012.766.013.49
Return on Assets-31.34-60.47-46.07-104.21-104.01-77.05
Return on Equity-34.18-74.47-55.00-182.55-162.04-111.42
Return on Invested Capital-5.03-11.83-11.28-82.18-117.73-42.92
Quick Ratio25.138.7610.011.531.231.80
Current Ratio25.138.7610.011.531.231.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-11.56-10.09-10.69-7.59-6.62-4.54
Depreciation0.130.130.090.130.080.06
Other Funds (Non Cash)0.940.600.570.470.530.87
Funds from Operations-10.49-9.36-10.03-6.98-6.01-3.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.25-0.47-1.001.070.701.93
Cash from Operating Activities-11.74-9.83-11.03-5.91-5.31-1.69
Capital Expenditures-0.02-0.03-0.17-0.37-0.13-0.07
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments2.69-4.77-6.480.000.000.00
Purchase of Investments-4.55-7.77-6.480.000.000.00
Sale Or Maturity of Investments7.243.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities2.67-4.80-6.65-0.37-0.13-0.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock155.28-0.0495.6710.611.110.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock155.28-0.0495.6710.611.110.00
Proceedsfrom Stock Options155.27-0.0795.5410.611.100.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities155.28-0.0495.6710.611.110.00
Exchange Rate Effect0.02-0.01-0.01-0.020.04-0.01
Net Change in Cash146.24-14.6877.984.31-4.28-1.76
Free Cash Flow-11.76-9.86-11.19-6.28-5.44-1.75

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.50%11.3M68.2M1.53M
2026-10-1515.70%10.7M68.2M1.64M
2026-09-3015.23%10.4M68.2M1.71M
2026-09-1516.34%9.6M58.9M1.84M
2026-08-3116.35%9.6M58.8M1.82M
2026-08-1417.61%10.4M58.8M1.86M
2026-07-3116.25%9.5M58.4M1.75M
2026-07-1514.55%8.5M58.4M1.54M
2026-06-3014.47%7.9M54.5M1.34M
2026-06-157.29%4.0M54.5M1.03M
2026-05-297.47%4.0M54.0M947.72K
2026-05-157.79%3.2M41.3M748.48K
2026-04-307.39%3.0M40.9M776.97K
2026-04-157.44%3.0M39.8M824.07K
2026-03-317.84%3.1M39.8M894.95K
2026-03-137.55%3.0M39.8M886.18K
2026-02-277.47%3.0M39.8M1.08M
2026-02-138.63%3.4M39.8M1.08M
2026-01-307.35%3.0M40.7M1.05M
2026-01-155.57%2.3M40.7M1.02M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.807.700.0023.4460.000.000.981-0.0170.001
call5.001.255.203.4310.0341310.000.956-0.0150.001
call7.500.251.951.513.66477.000.000.650-0.0770.004
call10.000.050.450.101.7249080.000.236-0.0400.004
call12.500.000.700.052.0646450.000.098-0.0270.002
call15.000.001.400.502.61573.000.000.081-0.0300.002
call17.500.001.850.083.0835930.000.072-0.0320.002
call20.000.000.400.053.7431190.000.126-0.0590.003
call22.500.000.401.054.09228.000.000.118-0.0620.003
call25.000.000.900.004.1320.000.000.059-0.0370.001
put2.500.001.850.004.6460.000.00-0.019-0.0160.001
put5.000.002.150.032.1041900.00-0.044-0.0150.001
put7.500.000.900.152.5798210.00-0.350-0.0760.004
put10.001.002.801.353.19681.000.00-0.764-0.0390.004
put12.502.155.700.005.1660.000.00-0.902-0.0260.002
put15.005.307.700.004.8180.000.00-0.919-0.0280.002
put17.507.3010.700.006.5880.000.00-0.928-0.0300.002
put20.009.8013.700.008.1940.000.00-0.934-0.0320.002
put22.5012.3016.200.008.6310.000.00-0.938-0.0330.001
put25.0014.8018.600.008.7930.000.00-0.941-0.0340.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-128-KCurrent report2026-11-12SEC
2026-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-27SCHEDULE 13GSEC
2026-09-308-KCurrent report2026-09-29SEC
2026-09-29FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-09-29424B5SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-06-05SCHEDULE 13G/ASEC
2026-05-298-KCurrent report2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-21424B5SEC
2026-05-21FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-04SCHEDULE 13G/ASEC
2026-04-06ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1210.04K200
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC13.74%
Saturn V Capital Management LP6.54%
EVENTIDE ASSET MANAGEMENT, LLC5.47%
STATE STREET CORP4.62%
BlackRock, Inc.4.20%
Deep Track Capital, LP3.90%
VANGUARD CAPITAL MANAGEMENT LLC3.52%
Opaleye Management Inc.3.29%
MILLENNIUM MANAGEMENT LLC2.90%
MARSHALL WACE, LLP2.52%

Funds

Fund% owned
Eventide Healthcare & Life Sciences Fund5.47%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.96%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.50%
T. Rowe Price Health Sciences Fund, Inc.1.86%
iShares Russell 2000 ETF1.50%
Columbia Small Cap Growth Fund1.05%
VANGUARD EXTENDED MARKET INDEX FUND0.96%
Columbia Small Cap Value Discovery Fund0.68%
Fidelity Small Cap Index Fund0.63%
iShares Russell 2000 Growth ETF0.52%

OakChart. IMMX. Cached 15 minutes. Terms